Image Credit: Zamora et al https://doi.org/10.1101/2020.09.10.292284
Amber Therapeutics has acquired fellow U.K.-based Bioinduction, a for its Picostim DyNeuMo platform. The implantable device was originally designed as a deep-brain stimulation device for the treatment of Parkinson’s disease. However, Amber intends to utilize it first as a pudendal nerve stimulator for treating mixed urinary incontinence, where patients experience symptoms of both stress and urge incontinence.
The device is currently being trialed in Belgium as part of a 15 female subject pilot study to evaluate its safety and efficacy.